Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

ASCO 2026

29 May - 2 Jun 2026

Published: 10 Jun 2026

Views: 2

Rating:

Save

Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Dr Filippo Pietrantonio speaks to ecancer about an analysis from the CodeBreaK 300 trial investigating circulating tumour DNA (ctDNA) as an early biomarker of treatment response in KRAS G12C-mutant metastatic colorectal cancer.

He reports that early ctDNA clearance was observed more frequently in patients receiving sotorasib plus panitumumab than in those receiving standard therapy, and was strongly associated with radiographic tumour shrinkage.

Dr Pietrantonios explains that these findings support early ctDNA clearance as a promising non-invasive biomarker for predicting treatment response and outcomes in patients receiving KRAS G12C-targeted therapy.

Related Videos

Tarlatamab improves brain metastases control and survival compared to chemo in...

Dr Giannis Mountzios - The University of Athens, Athens, Greece

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in...

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

Physical activity reduces fatigue and improves quality of life in colorectal...

Dr Louisa Liu - Cedars-Sinai Medical Center, Los Angeles, USA

Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors ( Dr Louisa Liu - Cedars-Sinai Medical Center, Los Angeles, USA )

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric...

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer ( Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada )

Consolidation treatment delays do not compromise survival in MRD-negative adult...

Prof Bhavana Bhatnagar - WVU Medicine Wheeling Hospital, Wheeling, USA

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL ( Prof Bhavana Bhatnagar - WVU Medicine Wheeling Hospital, Wheeling, USA )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna...

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer